Does exercise and protein really help preserve muscle during GLP-1 weight loss?
Yes — and the evidence is consistent across several studies. A 2024 study of 53 patients with type 2 diabetes found that those taking a GLP-1 drug who followed a 12-week structured program with increased protein intake (1-1.5 g per kg of adjusted body weight) and 360 minutes of exercise per week (with emphasis on strength training) lost no fat-free mass (muscle), while a similar group not on the drug lost 1.4 kg of muscle [1]. This suggests that the lifestyle intervention can offset the muscle loss typically seen with GLP-1 drugs.
A 2025 case series of three patients on semaglutide or tirzepatide who did resistance training 3-5 days per week and ate 1.6-2.3 g of protein per kg of fat-free mass showed even more striking results: two of the three patients actually gained lean soft tissue (by 2.5% and 5.8%) while losing substantial fat [4]. The third patient lost only 6.9% of weight as lean tissue, far less than the 26-40% seen in typical trials [4]. This shows that with the right support, muscle preservation — or even gain — is possible.
A 2024 pilot study in elderly obese patients (age 65+) found that adding semaglutide to a standard weight loss program (which included diet and exercise) resulted in significantly more fat loss and no significant difference in lean mass loss compared to the program alone [2]. The ratio of fat to lean mass improved in the semaglutide group, suggesting the drug itself may help spare muscle when combined with lifestyle measures.
Who needs to be most careful about muscle loss on GLP-1 drugs?
Older adults are at higher risk because aging already reduces muscle mass, and weight loss can accelerate that loss. The 2024 pilot study specifically focused on patients aged 65 and older and found that semaglutide plus a standard weight loss program led to more fat loss without significantly increasing lean mass loss compared to the program alone [2]. This is reassuring, but the study was small (16 patients) and short (16 weeks), so larger and longer trials are needed.
People with type 2 diabetes also need to be vigilant, as they often have lower muscle mass to begin with. The 2024 study in this population showed that without the intensive lifestyle intervention, GLP-1 users would likely lose muscle [1]. The good news is that the same study found that the structured program with protein and strength training completely prevented muscle loss in this group.
A 2025 review article concluded that combining GLP-1 drugs with regular exercise leads to greater weight loss effectiveness, lower reduction of lean body mass, and more durable weight reduction [3]. This supports the idea that everyone on these drugs should consider adding exercise and protein support, but the need is greatest for those already at risk of muscle loss.
What specific exercise and protein targets should you aim for?
Based on the studies, aim for at least 3-5 days per week of resistance training (strength exercises) [4], and a total of about 360 minutes of exercise per week (roughly 60 minutes, 6 days per week) that includes both aerobic and strength work [1]. The elderly study used a standard of care program that included dietary and exercise advice, though specific targets weren't detailed [2].
For protein, the studies used 1-1.5 g per kg of body weight per day [1], or 1.6-2.3 g per kg of fat-free mass per day [4]. For a 200-pound (90 kg) person, that means roughly 90-135 g of protein daily. This is higher than the general recommendation of 0.8 g/kg, reflecting the need to support muscle maintenance during calorie restriction.
It's important to note that these targets come from small studies (the largest had 53 participants [1], and the case series had only 3 [4]). While the results are promising, they are not definitive. A 2026 study found that a daily oral GLP-1 drug helped people maintain 75-79% of their earlier weight loss after stopping injections, but it did not specifically measure muscle preservation or the role of exercise and protein [5]. More research is needed to confirm the optimal exercise and protein doses.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2024 to 2026, 5 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 5 studies that passed quality screening, drawn from 58 papers retrieved from a database of over 500 million.
Sources used in this answer
14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists
In a 12-week retrospective study of 53 patients with type 2 diabetes, those on GLP-1 drugs who followed a structured program with increased protein (1-1.5 g/kg) and 360 min/week of exercise (emphasis on strength) lost no fat-free mass, while a similar group not on the drug lost 1.4 kg of muscle.
12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment
In a 16-week pilot study of 16 elderly obese patients (age 65+), adding semaglutide to a standard weight loss program resulted in significantly more fat loss (5.6 vs 1.5 kg) and no significant difference in lean mass loss compared to the program alone.
Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
A 2025 literature review concluded that combining GLP-1 drugs with regular exercise leads to greater weight loss, lower reduction of lean body mass, and more durable weight reduction.
Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series
In a case series of three patients on semaglutide or tirzepatide who did resistance training 3-5 days/week and ate 1.6-2.3 g protein per kg of fat-free mass, two patients gained lean soft tissue (2.5% and 5.8%) while losing substantial fat.
GLP-1: Daily pill reduces weight rebound after stopping injections, study suggests.
A 2026 study of 376 participants found that a daily oral GLP-1 drug helped people maintain 75-79% of their earlier weight loss after stopping injectable GLP-1s, but did not specifically examine muscle preservation or exercise/protein support.